Connect with us

Technology

Cerebral And Tissue Oximetry Devices Market size is set to grow by USD 96.3 million from 2024-2028, Growing use of cerebral and tissue oximetry devices in cardiac surgical procedures boost the market, AI Role and Impact, Technavio

Published

on

NEW YORK, Aug. 22, 2024 /PRNewswire/ — The global cerebral and tissue oximetry devices market size is estimated to grow by USD 96.3 million from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  8.08%  during the forecast period. Growing use of cerebral and tissue oximetry devices in cardiac surgical procedures is driving market growth, with a trend towards technological advances in cerebral and tissue oximetry devices. However, high cost of cerebral and tissue oximetry devices  poses a challenge. Key market players include Artinis Medical Systems, Boston Scientific Corp., Edwards Lifesciences Corp., GE Healthcare Technologies Inc., Hamamatsu Photonics KK, HyperMed Imaging Inc., ISS Inc., Masimo Corp., Medtronic Plc, Moor Instruments Ltd., Nonin Medical Inc., Sotera Health Co., Spectros Medical Devices Inc., Terumo Corp., and ViOptix Inc..

Get a detailed analysis on regions, market segments, customer landscape, and companies- View the snapshot of this report

Cerebral And Tissue Oximetry Devices Market Scope

Report Coverage

Details

Base year

2023

Historic period

2018 – 2022

Forecast period

2024-2028

Growth momentum & CAGR

Accelerate at a CAGR of 8.08%

Market growth 2024-2028

USD 96.3 million

Market structure

Concentrated

YoY growth 2022-2023 (%)

7.3

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 37%

Key countries

US, China, Germany, France, and Japan

Key companies profiled

Artinis Medical Systems, Boston Scientific Corp., Edwards Lifesciences Corp., GE Healthcare Technologies Inc., Hamamatsu Photonics KK, HyperMed Imaging Inc., ISS Inc., Masimo Corp., Medtronic Plc, Moor Instruments Ltd., Nonin Medical Inc., Sotera Health Co., Spectros Medical Devices Inc., Terumo Corp., and ViOptix Inc.

Market Driver

The cerebral and tissue oximetry devices market is witnessing significant advancements, driven by vendors’ focus on offering innovative products with enhanced features and benefits. Technological progressions, such as the adoption of diffuse correlation spectroscopy (DCS) technology for sensitive and rapid blood flow measurements and cerebral metabolism ratio of oxygen in deeply located tissues, are key factors fueling market growth. Vendors are also integrating continuous-wave light sources instead of pulsed laser and frequency-modulated approaches to reduce costs. Notable technology offerings include Medtronic’s INVOS TECHNOLOGY, which provides multi-sensor monitoring and real-time data on the balance of oxygen supply and demand using a 3:1 ratio of venous and arterial blood. Edward Lifesciences’ LASER-SIGHT optical technology increases the accuracy and reliability of cerebral and tissue oximetry devices by using five precise wavelengths of NIRS. Nonin Medical’s EQUANOX technology offers six channels for simultaneous monitoring of peripheral oxygen saturation (SpO2) and rSO2, along with dual detector and dual emitter sensors for enhanced accuracy. These advancements in NIRS technologies are crucial for end-users seeking precise and accurate measurements for routine healthcare operations. The increasing adoption of cerebral and tissue oximetry devices is expected to significantly boost the growth of the global cerebral and tissue oximetry devices market during the forecast period. 

The Cerebral and Tissue Oximetry Devices market is witnessing significant growth due to the increasing focus on monitoring oxygen saturation levels in various medical settings. Minimally invasive procedures using portable cerebral oximeter monitors are becoming popular among physicians for measuring cerebral oxygenation levels in cerebral tissues. These devices use sensors, a cable, oximeter probe, and a light detector with a fiber-optic light source to measure oxygen levels in the brain. The geriatric population and those with neurodegenerative diseases are major users of these devices. Oxygen saturation monitoring is essential during surgeries, ICUs, research settings, neonatal care, and for premature infants. Sensor technologies and data analytics are trending in this market, enabling real-time monitoring and improved patient care. Cerebral oximetry devices are used to monitor oxygen saturation levels in muscles, liver, and other tissues, besides the brain. These devices are available as tabletop models and portable, handheld units, catering to diverse requirements in hospitals and other healthcare facilities. 

Explore a 360° Analysis of the Market: Unveil the Impact of AI. For complete insights- Request Sample!

Market Challenges

The cost is a crucial factor for end-users when purchasing cerebral and tissue oximetry devices. The expense related to components and overall system hardware, including monitors, sensors, mounting options, and maintenance, significantly influences their buying decision. Advanced technologies, such as Near Infrared Spectroscopy (NIRS), used in these devices for accurate blood oxygenation monitoring, increase the overall cost. Monitors range from USD12,000 to USD25,000, and mounting options like wall mounts and roll stands can cost up to USD1,000. Sensor costs vary, with adult sensors priced between USD50 and USD100, and pediatric/infant sensors costing USD100USD150. Maintenance costs, primarily battery replacements, range from USD450 to USD550. Large-scale hospitals and clinical settings can justify these investments, but small healthcare facilities face challenges justifying the costs, potentially hindering the adoption and growth of the global cerebral and tissue oximetry devices market.The Cerebral and Tissue Oximetry Devices market is witnessing significant growth due to the increasing demand for non-invasive monitoring of oxygen saturation levels in various medical settings. These devices use sensors to measure tissue oxygen levels in muscles, liver, and during surgeries in ICUs, research settings, neonatal care, and premature infants. Sensor technologies and data analytics play a crucial role in providing real-time data for surgical procedures in operating rooms and outpatient settings. However, high device costs and complex reimbursement policies pose challenges to market growth. User-friendly design, portability, and flexibility are essential features for end-users. Tabletop devices are common in hospitals, while handheld devices offer convenience for healthcare professionals in diverse medical specialties, including neurological conditions, cardiovascular disorders, and heart disease. AI integration, wireless connectivity, and data analysis capabilities are emerging trends, enabling home healthcare and mobile monitoring systems for chronic diseases like peripheral artery disease. Surgeons and healthcare professionals rely on these devices for real-time data during surgeries, enhancing patient safety and outcomes.

For more insights on driver and challenges – Request a sample report!

Segment Overview 

This cerebral and tissue oximetry devices market report extensively covers market segmentation by  

Product 1.1 Modular devices1.2 Handheld devicesEnd-user 2.1 Hospitals2.2 ClinicsGeography 3.1 North America3.2 Europe3.3 Asia3.4 Rest of World (ROW)

1.1 Modular devices-  Handheld cerebral and tissue oximetry devices are compact, next-generation tools that provide instantaneous oxygen level measurements in blood without requiring direct patient contact or external connections to sensors and monitors. Advanced compatibility features enable these devices to pair with modular offerings from vendors, creating comprehensive solutions for medical practitioners during pre-operative, intra-operative, and postoperative assessments. Paired devices allow for real-time monitoring and decision-making during surgeries, saving valuable time. Proprietary spectrometer technology, such as HyperMed Imaging’s HyperView and ViOptix’s Intra.Ox, sets handheld devices apart from standard-of-care diagnostic imaging tools, which cannot distinguish oxygenated and deoxygenated hemoglobin. This advantage, along with applications in vascular procedures, wound care, and reconstructive surgeries, is fueling market growth for handheld cerebral and tissue oximetry devices.

For more information on market segmentation with geographical analysis including forecast (2024-2028) and historic data (2017-2021) – Download a Sample Report

Research Analysis

Cerebral and tissue oximetry devices measure oxygen saturation levels in cerebral tissues, including muscles and the liver. These devices are essential in various settings such as surgeries in ICUs, research settings, neonatal care for premature infants, and outpatient settings. Surgical procedures and operating rooms particularly benefit from real-time monitoring of cerebral oxygenation levels to ensure optimal patient care. High device costs and complex reimbursement policies pose challenges to widespread adoption. Advancements in technology include AI integration and wireless connectivity, enabling seamless integration into medical specialties treating chronic diseases and neurological conditions. Physicians rely on cerebral oximeter monitors, which include a cable and oximeter probe, typically placed on the forehead area. The device utilizes a light detector and fiber-optic light source to assess oxygen saturation levels in cerebral tissues.

Market Research Overview

Cerebral and tissue oximetry devices are non-invasive tools used to measure oxygen saturation levels in various tissues, including muscles, liver, and cerebral tissues. These devices use sensors to detect the amount of oxygen in the tissue based on the amount of light absorbed. They are used in various settings such as surgeries, ICUs, research settings, neonatal care, and home healthcare. Premature infants and patients with chronic diseases, neurological conditions, and cardiovascular disorders benefit from these devices. Sensor technologies have advanced to include data analytics, AI integration, and wireless connectivity, making them user-friendly, portable, and flexible. Handheld devices and tabletop devices are popular due to their portability and real-time data capabilities. High device costs and reimbursement policies are challenges in the market. These devices are used in surgical procedures, operating rooms, outpatient settings, and minimally invasive procedures. Surgeons and healthcare professionals rely on cerebral oximeter monitors to monitor cerebral oxygenation levels in the brain, especially during cardiac surgeries and cardiovascular diseases. Geriatric population with neurodegenerative diseases also benefits from these devices. Oxygen saturation levels are essential indicators of tissue health, and these devices provide valuable information for medical specialties to make informed decisions.

Table of Contents:

1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation

ProductModular DevicesHandheld DevicesEnd-userHospitalsClinicsGeographyNorth AmericaEuropeAsiaRest Of World (ROW)

7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

View original content to download multimedia:https://www.prnewswire.com/news-releases/cerebral-and-tissue-oximetry-devices-market-size-is-set-to-grow-by-usd-96-3-million-from-2024-2028–growing-use-of-cerebral-and-tissue-oximetry-devices-in-cardiac-surgical-procedures-boost-the-market-ai-role-and-impact-technavio-302228668.html

SOURCE Technavio

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

RIVANNA nominated for MedTech Scale-Up of the Year at MedTech World Awards 2026 | North America

Published

on

By

Nomination places the Charlottesville-based company among growth-stage medtech leaders recognized for commercial momentum in AI-powered clinical decision support; public voting is open through May 8

CHARLOTTESVILLE, Va., May 5, 2026 /PRNewswire/ — RIVANNA®, developer of AI-powered clinical decision-support solutions, today announced that it has been nominated for MedTech Scale-Up of the Year at the MedTech World Awards 2026 | North America. Public voting is open through Friday, May 8, 2026, with category winners to be announced at the inaugural North American Awards Gala on May 11, 2026, at the Hilton West Palm Beach in Florida.

The MedTech Scale-Up of the Year category honors a growth-stage company successfully scaling revenues, partnerships, and adoption across the global medical technology ecosystem. Nominees across the program’s 22 categories were selected through a structured process led by the MedTech World Steering Committee, with category winners determined by a combination of expert evaluation and public voting from the global MedTech community.

“We have built RIVANNA on validation earned from the most rigorous technical buyers in healthcare: competitive federal awards translated into FDA-cleared products, each paired with a commercial program that meets clinicians where they work,” said Will Mauldin, PhD, Co-founder and CEO of RIVANNA. “Being nominated for MedTech Scale-Up of the Year is a meaningful affirmation of that approach and the team executing it.”

Public voting closes Friday, May 8, 2026. Members of the MedTech community are invited to support RIVANNA’s nomination at the official voting page: vote here.

The award nomination follows a year of measurable scaling for RIVANNA:

In October 2025, RIVANNA reported on being named a finalist in MedTech Innovator’s 2025 Early-Stage Grand Prize competition, selected from nearly 1,500 global applicants to represent the top 4% of medtech innovations worldwide.In December 2025, RIVANNA reported on the U.S. Food and Drug Administration’s 510(k) clearance of its Accuro® 3S Needle Guide Kit consumables, building on existing Accuro 3S device clearance.In April 2026, RIVANNA reported on peer-reviewed findings, published in 2025 in the Journal of Emergency Medicine (DOI: 10.1016/j.jemermed.2025.11.011), showing that the Accuro® XV musculoskeletal imaging system enables non-physician operators to acquire diagnostic-quality scans after just one hour of hands-on training.In May 2026, RIVANNA reported on the U.S. Food and Drug Administration’s 510(k) clearance of the Accuro® XV Diagnostic Ultrasound System for musculoskeletal imaging, authorizing commercial use across hospital and clinic settings.The company’s clinical program now spans eight sites nationwide with more than 1,500 patients enrolled.

The 2026 MedTech World Awards | North America, powered by Blue Goat Cyber, will be presented Monday, May 11, 2026, at the inaugural North American Awards Gala at the Hilton West Palm Beach, marking the first time the MedTech World Awards have been hosted in the United States.

About the MedTech Scale-Up of the Year Award
Presented by MedTech World, the MedTech Scale-Up of the Year category recognizes growth-stage medical technology companies demonstrating strong commercial momentum, expanding partnerships, and accelerating real-world adoption. The award is one of 22 categories spanning innovation, clinical excellence, regulatory strategy, investment, and leadership across the global MedTech ecosystem.

About RIVANNA
RIVANNA® is a medical technology company developing clinical decision-support solutions powered by proprietary clinical datasets, AI models, and purpose-built imaging hardware. The company’s platform automates complex anatomical analysis at the point of care, enabling faster, more confident clinical decisions while reducing variability and expanding access to advanced capabilities. The first applications target significant market opportunities in regional anesthesia and fracture care. RIVANNA has built a proven FDA regulatory track record across its Accuro® platform, with device clearances for Accuro® 3S (spinal needle guidance) and Accuro® XV (musculoskeletal imaging), a portfolio of supporting cleared consumables, and AI software modules advancing through regulatory review. The company is backed by 100+ patents and validated through clinical partnerships with leading academic medical centers. RIVANNA is headquartered in Charlottesville, Virginia, and operates an FDA-registered, ISO 13485:2016-certified manufacturing facility. Learn more at rivannamedical.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/rivanna-nominated-for-medtech-scale-up-of-the-year-at-medtech-world-awards-2026–north-america-302763342.html

SOURCE RIVANNA

Continue Reading

Technology

D2L Launch Week Highlights Latest Product Releases

Published

on

By

Latest innovations are designed to save time, simplify workflows, and help drive better learning outcomes

TORONTO, May 5, 2026 /PRNewswire/ – D2L, a global leader in learning innovation, hosted its first-ever D2L Launch Week, a four-day virtual webinar series spotlighting the company’s latest product innovations across D2L Brightspace in 2026.

Throughout the week, D2L showcased a range of product releases through live demos and practical customer use cases, highlighting how institutions, school districts and organizations can help to drive engagement and improve learning outcomes. The featured updates include enhancements to D2L Lumi for idea generation, intervention suggestions, quiz creation and summarization; tools to strengthen parent and guardian outreach; and administrative capabilities designed to help large organizations delegate course and configuration management more effectively.

“We’re proud to showcase the ways D2L continues to innovate to help make learning more personalized, efficient, and scalable,” said Christian Pantel, Chief Product Officer at D2L. “From new D2L Lumi features to enhanced communication tools and more flexible distributed administration capabilities, these updates are designed to help our customers save time, improve usability, and deliver better learning experiences at scale.”

Enhancements to D2L Lumi

Among the new capabilities were several updates to D2L’s AI-native tool, D2L Lumi, designed to improve usability, transparency, and alignment across workflows, including:

D2L Lumi Ideas: Generates assignment and discussion ideas directly within Brightspace, making it easier to generate high quality content aligned to learning outcomes.D2L Lumi Insights: Gives educators access to learning intervention suggestions, designed to provide recommended next steps based on learner data.D2L Lumi Quiz: Helps educators generate questions from multiple course content topics and includes a more streamlined question-generation workflow.D2L Lumi Summary: Supports summarization from more content sources, including nested submodules, and can give educators the ability to preview and adjust source text before summarization.

Updates to Parent and Guardian Communications

D2L also introduced new parent and guardian communication enhancements to help K-12 educators strengthen engagement beyond the classroom. Teachers can now send bulk emails to all parents and guardians associated with students in their class. For individual student outreach, teachers can also email parents and guardians of a specific learner, making it easier to share timely updates on student progress and classroom activity.

Manage Distributed Administration at Scale

Distributed Administration gives organizations more flexibility to delegate administrative responsibilities across organization levels. With Distributed Administration, administrators can manage specific areas, enabling them to oversee courses while helping to reduce bottlenecks and free up time.

Learn more about the latest product releases showcased at D2L Launch Week.

About D2L   
D2L is transforming the way the world learns, helping learners achieve more than they dreamed possible. Working closely with customers all over the world, D2L is on a mission to make learning more inspiring, engaging and human. Find out how D2L helps transform lives and delivers outstanding learning outcomes in K-12, higher education and businesses.

D2L Media Contact
PR@D2L.com
X: @D2L
© 2026 D2L Corporation.

The D2L family of companies includes D2L Inc., D2L Corporation, D2L Ltd, D2L Australia Pty Ltd, D2L Europe Ltd, D2L Asia Pte Ltd, D2L India Pvt Ltd, D2L Brasil Soluções de Tecnologia para Educação Ltda and D2L Sistemas de Aprendizaje Innovadores, S. D2 R.L de C.V., and H5P Group AS.

All D2L and H5P marks are owned by the D2L group of companies. Please visit D2L.com/trademarks for a list of D2L marks. All other trademarks are the property of their respective owners.

View original content to download multimedia:https://www.prnewswire.com/news-releases/d2l-launch-week-highlights-latest-product-releases-302763345.html

SOURCE D2L

Continue Reading

Technology

Ultima Markets Celebrates 10th Anniversary

Published

on

By

10 Years of Trust. Focused on Tomorrow.

EBENE CYBERCITY, Mauritius, May 5, 2026 /PRNewswire/ — Ultima Markets Ltd (“UM”), authorised and regulated by the Financial Services Commission of Mauritius, marks its 10th anniversary under the theme, “10 Years of Trust. Focused on Tomorrow.” Since 2016, UM has transformed into a leading global brokerage.

Milestones

UM built a world-class trading space through ultra-fast tech and strict compliance, launching the UM Terminal, AI-driven MT5, and Mobile App. Key milestones include FSC Mauritius Authorisation (2023), a Willis Towers Watson partnership providing $1M fund protection, joining the UN Global Compact (2024), and securing 50+ awards by 2026.

Celebrating Lasting Partnerships

Exclusive initiatives include:

Ultimate Trader Cup: An epic trading competition to prove your edge.Ultima Loyalty Programme: A tiered system turning loyalty into long-term rewards.Ultima Partnership Programme: Leverage 10 years of market trust into lasting revenue.Inter Partnership Perks: VIP events and match access via its Inter partnership.

The Five ‘U’s

Core values guiding UM’s next decade:

User: Designing around trader needs and removing friction.United: Fostering community growth through learning.Upright: Acting transparently and ethically.Upward: Pursuing continuous product and performance growth.Upgrade: Elevating trader skills, tools, and outcomes.

Focused on Tomorrow

Guided by The Five ‘U’s, UM remains focused on tomorrow, investing in innovation, transparency, and global expansion. Building on recent advancements like Copy Trading Pro and UM Academy, its commitment is providing the ultimate trading edge and elite support worldwide.

About Ultima Markets

Ultima Markets Ltd is authorised and regulated by the Financial Services Commission of Mauritius, offering a secure, regulated CFD trading experience. As the Official Regional Partner of FC Internazionale Milano, UM unites football passion with trading knowledge. Serving 170+ countries with 1,000+ instruments, the broker is a 50+ award winner and proud UN Global Compact supporter, aligning with Sustainable Development Goals for responsible growth. The products, services and initiatives described in this press release are offered exclusively by Ultima Markets Ltd. This communication is not directed at, nor are the products and services described herein available to, residents of the United Kingdom.

Ultima Markets (UK) Limited (“UM UK”) is a distinct legal entity authorised and regulated by the Financial Conduct Authority (“FCA”) in the United Kingdom. UM UK secured its FCA authorisation in 2025. UM UK is not the subject of this press release.

Photo – https://mma.prnewswire.com/media/2970209/10th_Anniverary_Company_News_Banner.jpg
Logo – https://mma.prnewswire.com/media/2833372/5947525/NEW_vs_OLD_On_white_01_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/ultima-markets-celebrates-10th-anniversary-302763362.html

Continue Reading

Trending